Relative Strength Chart Akeso, Inc.

Equities

Market Closed - Hong Kong S.E. Other stock markets 01:38:07 16/07/2025 pm IST			5-day change	1st Jan Change
126.00 ^HKD	+4.39%		+14.75%	+107.58%

10:50am	Akeso, Inc. Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	CI
03/07	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	RE

End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	AKESO, INC.	Bio Therapeutic Drugs	+4.39%	+14.75%	+107.58%	+226.85%	+256.44%	1.38TCr